News

Vanda's tasimelteon meets Phase III endpoint in delayed sleep-wake disorder, advancing 60% of patients' sleep onset by 30+ minutes...

AbbVie's zumilokibart met all primary endpoints in Phase 2 atopic dermatitis testing, showing rapid skin and itch improvement with...

Plinabulin earns FDA Fast Track Status for advanced NSCLC after ICI failure, advancing BeyondSpring's DUBLIN-4 Phase 3 trial in...

FDA Single IRB Rule for multisite trials advances to final rule status in December 2026, ending parallel IRB review...

Novo Nordisk licenses oral GLP-1/GIP dual agonist HRS-1596 from Hengrui for $300M upfront, with potential $2.6B in milestone payments.

Keros Therapeutics enrolls first patient in Phase 2 rinvatercept DMD trial to evaluate myostatin/activin inhibition for Duchenne muscular dystrophy.

CIRM awards Fate Therapeutics $15M to advance FT819 lupus nephritis trial, testing allogeneic CAR T-cell therapy in patients failing...

4D-150 Gene Therapy enters Phase 3 testing for diabetic macular edema, aiming to replace recurring anti-VEGF injections with a...

FDA approves DEGEVMA biosimilar to Xgeva for cancer bone complications, expanding the competitive denosumab market following Sandoz's earlier approval.

Inventiva's lanifibranor faces cash runway pressure as it awaits Phase 3 MASH data readout. Enrollment pace will determine financing...